Pfizer exceeds fourth-quarter expectations but starts 2023 with low forecast

Pfizer exceeds fourth-quarter expectations but starts 2023 with low forecast
Covid-19 booster vaccines and treatments for coronavirus helped push Pfizer to a better-than-expected final quarter of 2022 (Mark Lennihan/AP)

Covid-19 booster vaccines and treatments for coronavirus helped push Pfizer to a better-than-expected final quarter of 2022.

However, the pharmaceutical giant announced on Tuesday a 2023 forecast that starts off well below Wall Street forecasts.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited